{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Germ+Cell+and+Embryonal&page=13", "query": { "condition": "Neoplasms, Germ Cell and Embryonal", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 5147, "total_pages": 515, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Germ+Cell+and+Embryonal&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neoplasms%2C+Germ+Cell+and+Embryonal&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T14:06:39.168Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04416568", "title": "Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Rhabdoid Tumor", "Rhabdoid Tumor of the Kidney", "Epithelioid Sarcoma", "Chordoma (Poorly Differentiated or De-differentiated)", "Atypical Teratoid/Rhabdoid Tumor", "Other INI1 Negative Tumors (With PI Approval)", "Other SMARCA4-deficient Malignant Tumors (With PI Approval)" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "6 Months to 40 Years" }, "enrollment_count": 30, "start_date": "2020-08-14", "completion_date": "2027-07-01", "has_results": true, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-11-15T14:06:39.168Z", "location_count": 8, "location_summary": "San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04416568" }, { "nct_id": "NCT00823797", "title": "Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Neoplasm" ], "interventions": [ { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2008-10", "completion_date": "2017-04", "has_results": true, "last_update_posted_date": "2017-07-07", "last_synced_at": "2026-11-15T14:06:39.168Z", "location_count": 3, "location_summary": "Chicago, Illinois • Salt Lake City, Utah • Seattle, Washington", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00823797" }, { "nct_id": "NCT00006102", "title": "Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma", "Neuroblastoma", "Retinoblastoma", "Sarcoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "becatecarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 200, "start_date": "2000-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-05", "last_synced_at": "2026-11-15T14:06:39.168Z", "location_count": 198, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 149 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006102" }, { "nct_id": "NCT04762602", "title": "A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Isocitrate Dehydrogenase Gene Mutation" ], "interventions": [ { "name": "HMPL-306", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchmed", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2021-02-28", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-11-15T14:06:39.168Z", "location_count": 8, "location_summary": "Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 4 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04762602" }, { "nct_id": "NCT06358001", "title": "EchoTip AcuCore Post-Market Clinical Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma", "Neuroendocrine Tumors", "Hepatocellular Carcinoma", "Cholangiocarcinoma", "Malignant Lymphoma", "Metastasis", "Chronic Pancreatitis", "Autoimmune Pancreatitis" ], "interventions": [ { "name": "EchoTip AcuCore", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cook Research Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 183, "start_date": "2024-08-05", "completion_date": "2025-07-19", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-11-15T14:06:39.168Z", "location_count": 8, "location_summary": "Orange, California • Denver, Colorado • Gainesville, Florida + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06358001" }, { "nct_id": "NCT00227032", "title": "Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2005-09", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2012-03-06", "last_synced_at": "2026-11-15T14:06:39.168Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00227032" }, { "nct_id": "NCT00400816", "title": "Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Tumors", "Brain Tumor" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2005-08", "completion_date": "2016-01-06", "has_results": false, "last_update_posted_date": "2018-09-18", "last_synced_at": "2026-11-15T14:06:39.168Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00400816" }, { "nct_id": "NCT00006799", "title": "Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anorexia", "Cachexia", "Head and Neck Cancer", "Quality of Life" ], "interventions": [ { "name": "megestrol acetate", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 13, "start_date": "2000-10-01", "completion_date": "2002-09-06", "has_results": false, "last_update_posted_date": "2021-09-09", "last_synced_at": "2026-11-15T14:06:39.168Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006799" }, { "nct_id": "NCT04526899", "title": "A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma Stage III", "Melanoma Stage IV", "Unresectable Melanoma" ], "interventions": [ { "name": "BNT111", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2021-05-19", "completion_date": "2025-11-24", "has_results": true, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-11-15T14:06:39.168Z", "location_count": 6, "location_summary": "Tucson, Arizona • San Francisco, California • Miami, Florida + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04526899" }, { "nct_id": "NCT01496807", "title": "Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Sylatron", "type": "DRUG" }, { "name": "Yervoy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 31, "start_date": "2012-02-17", "completion_date": "2016-08-29", "has_results": true, "last_update_posted_date": "2017-04-28", "last_synced_at": "2026-11-15T14:06:39.168Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01496807" } ] }